Posts by: Marta Figueiredo

Marta Figueiredo

October 10, 2019October 10, 2019

Blocking LRP1 May Halt Inflammation, Promote Remyelination, Mouse Study Suggests

News

Blocking production of the low-density lipoprotein receptor-related protein 1 (LRP1) — involved in inflammatory and immune responses — specifically in myelin repair cells halts neuroinflammation and promotes myelin repair, a ... Read more

September 9, 2019September 10, 2019

Inflammation Hijacks Myelin Repair Cells to Promote Immune Attacks, Study Shows

News

Brain inflammation in multiple sclerosis (MS) hijacks immature myelin repair cells, not only preventing myelin restoration but also promoting sustained inflammation and immune attacks against myelin, a preclinical study shows. The ... Read more

September 4, 2019September 4, 2019

Targeting Inflammatory Th17 Cells to Slow MS Disability Possible with Fewer Side Effects, Study Suggests

News

Scientists may have found a way to manipulate T-helper 17 (Th17) cells so as to lower their ability to trigger inflammation, delaying the onset of multiple sclerosis (MS) in a mouse ... Read more

August 26, 2019September 3, 2019

Persistent MS-related Fatigue Linked to Damage in Specific Brain Regions, Study Finds

News

Persistent fatigue in people with multiple sclerosis (MS) is associated with damage in specific areas of the brain, regardless of depression symptoms, a study shows. The study, “Microstructural fronto-striatal ... Read more

August 6, 2019August 6, 2019

Phase 1 Study Finds T20K, Plant Protein-derived Compound for MS, Safe and Tolerable, Cyxone Says

News

A Phase 1 clinical trial found T20K, Cyxone’s investigational plant protein-derived treatment for multiple sclerosis (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work ... Read more

September 6, 2018September 6, 2018

Tysabri Seen to Improve Cognition in RRMS Patients Over 2 Years in Retrospective Study

News

Tysabri (natalizumab) was reported in a small retrospective study to significantly improve cognitive abilities in people with relapsing-remitting MS patients (RRMS) over two years of use. The study, “Improvement in Cognitive ... Read more

September 4, 2018September 6, 2018

Spasticity Scales May Not Be Sufficiently Informative of Sativex Benefits in MS Patients, Small Study Suggests

News

Spasticity scales may be insufficient to reflect the actual benefits of Sativex (nabiximols) treatment on spasticity symptoms in people with multiple sclerosis (MS), according to a small case series ... Read more

August 30, 2018September 3, 2018

Tecfidera, Gilenya Equally Effective, But More MS Patients Stop Tecfidera, Real-World Study Shows

News

Tecfidera (dimethyl fumarate) and Gilenya (fingolimod) are equally effective in treating multiple sclerosis (MS), but Tecfidera shows higher rates of discontinuation, according to a real-world study. The study, “Discontinuation and comparative effectiveness ... Read more

August 17, 2018August 24, 2018

Most MS Patients OK With Intravenous Treatment Conditions, Study Suggests

News

Most patients with multiple sclerosis (MS) are satisfied with the conditions of their intravenous therapy (administered directly into the bloodstream) and are very aware of the therapy’s safety, according to ... Read more

August 3, 2018August 7, 2018

Blood Levels of IgG3 Antibodies May Predict Faster Shift to MS in Clinically Isolated Syndrome Patients, Study Says

News

Higher-than-usual levels of specific antibodies in the blood of patients with clinically isolated syndrome (CIS) may predict a faster progression to multiple sclerosis, an Australian study reports. The specific antibody is known ... Read more

August 1, 2018August 9, 2018

Ozanimod Effectively Lowers Relapse Rates in MS Patients, Data from 2-Year Extension Study Show

News

Being treated with ozanimod consistently reduced disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to results of a two-year extension of a Phase 2 trial. These benefits were ... Read more

April 24, 2018April 24, 2018

Compound Produced by Immune Cells May Hold Promise for Multiple Sclerosis

News

A compound produced by immune cells is able to treat psoriasis – a skin disorder – in mice, and may be effective against other autoimmune diseases, such as multiple ... Read more

December 27, 2017December 20, 2017

U.K. Survey Supports Likelihood of Link Between Chicken Pox-Shingles Virus and MS

News

A large U.K. survey assessing the frequency of chickenpox and shingles in multiple sclerosis (MS) patients suggests a link between these diseases and MS, researchers report, suggesting their findings ... Read more

December 5, 2017December 5, 2017

Laquinimod Fails to Slow Brain Atrophy and PPMS Progression, Says Developer Active Biotech

News

Sweden’s Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of Phase 2 clinical trial evaluating the drug’s potential to treat primary progressive multiple sclerosis. Laquinimod, also known as Nerventra or ABR-215062, ... Read more

December 1, 2017December 2, 2017

Mayo Clinic Develops Test to Distinguish Other Demyelinating Diseases from MS

News

The Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis in the early stages of a disorder. The test, the ... Read more

November 22, 2017November 22, 2017

Smoking Alters DNA-based Mechanism That Influences Gene Activity in MS, Study Confirms

News

Smoking changes a DNA-based mechanism that influences multiple sclerosis patients’ gene activity, a Swedish study confirms. Another finding was that MS appears to aggravate the harmful effects of smoking. ... Read more

November 9, 2017November 14, 2017

Survey Helps Improve Communication Between Women with MS and Healthcare Providers

News

A national survey in the U.S. revealed that 98% of women newly diagnosed with multiple sclerosis struggle to discuss important personal concerns with their healthcare team. The survey was conducted ... Read more